Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

LXRX

Lexicon Pharmaceuticals Inc

Dec 13 • 04:00PM ET

0.8103

Dollar change -0.0119
Percentage change -1.45	%

Healthcare • Biotechnology • USA • NASD

Peers: VRTX BIIB REGN BMRN INCY ALNY IONS NBIX KNSA ALLO

| Held by: VTI VXF IWM VTWO SCHA IWN IWO IWC BBP SCHB

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-0.75	Insider Own	53.35%	Shs Outstand	361.49M	Perf Week	14.92%
Market Cap	292.92M	Forward P/E	-	EPS next Y	-0.46	Insider Trans	0.00%	Shs Float	168.63M	Perf Month	-25.66%
Income	-214.88M	PEG	-	EPS next Q	-0.13	Inst Own	29.64%	Short Float	18.70%	Perf Quarter	-52.34%
Sales	5.23M	P/S	56.01	EPS this Y	14.05%	Inst Trans	7.06%	Short Ratio	8.48	Perf Half Y	-55.72%
Book/sh	0.49	P/B	1.64	EPS next Y	32.56%	ROA	-71.91%	Short Interest	31.53M	Perf Year	-31.33%
Cash/sh	0.71	P/C	1.13	EPS next 5Y	-	ROE	-135.14%	52W Range	0.62 - 3.73	Perf YTD	-47.04%
Dividend Est.	-	P/FCF	-	EPS past 5Y	6.80%	ROI	-75.91%	52W High	-78.28%	Beta	1.06
Dividend TTM	-	Quick Ratio	7.43	Sales past 5Y	186.21%	Gross Margin	82.90%	52W Low	30.61%	ATR (14)	0.11
Dividend Ex-Date	-	Current Ratio	7.45	EPS Y/Y TTM	1.42%	Oper. Margin	-4037.43%	RSI (14)	40.31	Volatility	18.50% 12.31%
Employees	285	Debt/Eq	0.59	Sales Y/Y TTM	884.75%	Profit Margin	-4109.41%	Recom	1.67	Target Price	3.60
Option/Short	Yes / Yes	LT Debt/Eq	0.59	EPS Q/Q	13.09%	Payout	-	Rel Volume	2.52	Prev Close	0.82
Sales Surprise	-41.54%	EPS Surprise	-10.57%	Sales Q/Q	980.25%	Earnings	Nov 12 AMC	Avg Volume	3.72M	Price	0.81
SMA20	1.35%	SMA50	-37.21%	SMA200	-52.93%	Trades		Volume	9,361,831	Change	-1.45%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-17-24	Initiated	H.C. Wainwright	Buy	$10
Apr-30-24	Initiated	Leerink Partners	Outperform	$5
Mar-07-23	Initiated	Jefferies	Hold	$3
Aug-12-22	Initiated	Piper Sandler	Overweight	$10
Jan-29-21	Upgrade	JP Morgan	Underweight → Neutral	$7
Jan-29-21	Downgrade	Wedbush	Outperform → Neutral	$2 → $8
Dec-08-20	Upgrade	Citigroup	Neutral → Buy
Nov-18-20	Upgrade	Gabelli & Co	Hold → Buy
Dec-11-19	Downgrade	Gabelli & Co	Buy → Hold
Nov-08-19	Downgrade	Citigroup	Buy → Neutral	$3 → $4
Sep-11-19	Upgrade	Gabelli & Co	Hold → Buy	$3
Jul-29-19	Downgrade	Stifel	Buy → Hold	$10 → $4
Mar-25-19	Upgrade	Gabelli & Co	Sell → Hold
Jul-31-18	Reiterated	Stifel	Buy	$24 → $23
Feb-23-18	Downgrade	Needham	Buy → Hold
Feb-14-18	Downgrade	JP Morgan	Neutral → Underweight	$10
Mar-01-17	Reiterated	Wedbush	Outperform	$33 → $38
Mar-01-17	Reiterated	H.C. Wainwright	Buy	$26 → $27
Oct-07-16	Initiated	H.C. Wainwright	Buy	$26
Aug-05-16	Reiterated	Wedbush	Outperform	$30 → $31

Show Previous Ratings

Nov-27-24 07:30AM	Lexicon completes subject enrolment for DPNP trial of LX9211 (Clinical Trials Arena)
Nov-26-24 08:00AM	Lexicon Announces Completion of Enrollment in Phase 2B PROGRESS Study of LX9211 in Diabetic Peripheral Neuropathic Pain (DPNP) (GlobeNewswire)
Nov-25-24 04:15PM	Lexicon Pharmaceuticals to Participate in December Investor Conferences (GlobeNewswire) -5.81%
Nov-22-24 07:32AM	Lexicon to Reposition as Clinical Development-Focused Company Following Regulatory Update From FDA (GlobeNewswire) +11.88%
05:05AM	Lexicon to disband sales team, lay off 60% of staff (BioPharma Dive)
04:05PM	Loading…
Nov-20-24 04:05PM	Lexicon Appoints Ivan H. Cheung to Board of Directors (GlobeNewswire) -8.34%
Nov-14-24 08:00AM	Post-Hoc Analysis Demonstrating Sotagliflozin Benefits Across Broad Spectrum of Heart Failure Patient Populations is Among Four Lexicon-Supported Presentations at the American Heart Association's (AHA) Sessions 2024 in Chicago (GlobeNewswire)
Nov-13-24 02:20AM	Lexicon Pharmaceuticals Inc (LXRX) Q3 2024 Earnings Call Highlights: Strategic Advances Amidst ... (GuruFocus.com) -8.40%
Nov-12-24 05:25PM	Lexicon Pharmaceuticals (LXRX) Reports Q3 Loss, Lags Revenue Estimates (Zacks) -6.30%
04:25PM	Lexicon: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Lexicon Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Nov-11-24 07:15AM	Lexicon Pharmaceuticals Inc (LXRX) Q3 2024 Earnings Report Preview: What To Look For (GuruFocus.com)
Nov-07-24 05:02PM	S&P 500 Gains and Losses Today: Index Ticks Higher as Fed Trims Benchmark Rate (Investopedia) +7.44%
Nov-06-24 08:00AM	Lexicon Pharmaceuticals to Participate in the Jefferies London Global Healthcare Conference (GlobeNewswire)
02:58AM	A diabetes drug, twice rejected, stumbles again but its developer persists (Pharma Voice)
04:05PM	Loading…
Nov-05-24 04:05PM	Published Data in Journal of American Society of Nephrology Highlights Findings on Efficacy and Safety of Sotagliflozin for People With Type 1 Diabetes and Chronic Kidney Disease (GlobeNewswire)
08:00AM	Lexicon Pharmaceuticals to Host Third Quarter 2024 Financial Results Conference Call and Webcast on November 12, 2024 (GlobeNewswire)
Nov-04-24 08:00AM	Lexicon to Present Preclinical IN VIVO Efficacy Data Demonstrating Ability of New Investigational Compound to Enhance and Maintain Semaglutide-Promoted Weight Loss (GlobeNewswire)
Oct-31-24 06:54PM	Lexicon Announces Outcome of FDA Advisory Committee for Zynquista (sotagliflozin) as an Adjunct to Insulin Therapy for Glycemic Control in Adults with Type 1 Diabetes and Chronic Kidney Disease (GlobeNewswire)
Oct-27-24 05:35PM	FDA Endocrinologic and Metabolic Drugs Advisory Committee to hold a meeting (TipRanks)
Oct-23-24 09:00AM	New Analysis of Phase 3 Data Demonstrating Renal Protective Benefits of Sotagliflozin to be Presented at ASN Kidney Week 2024 (GlobeNewswire)
Oct-22-24 08:00AM	Lexicon Announces Completion of Screening in Phase 2B Progress Study of LX9211 in Diabetic Peripheral Neuropathic Pain (DPNP) (GlobeNewswire)
Oct-17-24 07:15AM	Lexicon sells Viatris rights to cardio drug outside of the U.S. and Europe (BioPharma Dive) +5.24%
05:55AM	Lexicon partners Viatris for global expansion of sotagliflozin (Pharmaceutical Technology)
Oct-16-24 04:35PM	Lexicon Announces Exclusive Licensing Agreement With Viatris for Sotagliflozin in All Markets Outside of the U.S. and Europe (GlobeNewswire) +6.70%
04:34PM	Viatris Announces Exclusive Licensing Agreement with Lexicon Pharmaceuticals for Sotagliflozin in all Markets Outside of the U.S. and Europe (PR Newswire)
Oct-09-24 03:53PM	Lexicon Pharmaceuticals Inc (LXRX) Q2 2024 Earnings Call Highlights: Strategic Advancements ... (GuruFocus.com)
Sep-27-24 08:00AM	Lexicon to Present Phase 3 Trial Design for Sotagliflozin in Hypertrophic Cardiomyopathy (HCM) at Upcoming Medical Congress (GlobeNewswire)
Sep-16-24 08:00AM	Lexicon Pharmaceuticals Announces Departure of President and Chief Operating Officer (GlobeNewswire)
Sep-10-24 08:00AM	New Secondary Analysis of Phase 3 Data Demonstrates Sotagliflozin Improves Time-In-Range (TIR) and Several Parameters of Glucose Control and Variability in Basal Insulin-Treated Type 2 Diabetes (GlobeNewswire)
04:00PM	Loading…
Sep-03-24 04:00PM	Lexicon Pharmaceuticals to Participate in Upcoming September Investor Conferences (GlobeNewswire) -6.94%
08:00AM	New Secondary Analysis of Phase 3 Data Demonstrates that INPEFA (Sotagliflozin) Benefited Heart Failure Patients Regardless of Diabetes Duration (GlobeNewswire)
Sep-01-24 10:26PM	Lexicon Pharmaceuticals, Inc. (LXRX): The Best Multibagger Penny Stock of 2025? (Insider Monkey)
Aug-29-24 08:41PM	10 Best Multibagger Penny Stocks of 2025 (Insider Monkey)
Aug-22-24 11:26AM	Lexicon (LXRX) Up as FDA Maintains Action Date for Zynquista (Zacks)
10:33AM	Lexicon to face FDA AdComm for Zynquista approval in diabetes and CKD (Pharmaceutical Technology)
Aug-21-24 08:00AM	Lexicon Pharmaceuticals Announces FDA Advisory Committee Meeting for Zynquista (GlobeNewswire) +13.69%
Aug-14-24 12:33PM	Lexicon (LXRX) to Reprioritize Portfolio, Slash Jobs, Stock Up (Zacks) -5.20%
Aug-13-24 08:30AM	Lexicon Pharmaceuticals Announces Strategic Repositioning to Drive Value and Growth of Commercial Portfolio (GlobeNewswire) +8.81%
07:00AM	Lilly opens R&D hub; Ovid and Lexicon lay off staff (BioPharma Dive)
Aug-07-24 08:00AM	Efficacy and Safety Data of Sotagliflozin in Patients with Type 1 Diabetes and Chronic Kidney Disease Among Three Lexicon-Sponsored Presentations at the 2024 Annual Conference of the Association of Diabetes Care & Education Specialists (GlobeNewswire)
Aug-01-24 05:15PM	Lexicon Pharmaceuticals (LXRX) Reports Q2 Loss, Misses Revenue Estimates (Zacks) -10.22% -16.09%
04:12PM	Lexicon: Q2 Earnings Snapshot (Associated Press Finance)
04:00PM	Lexicon Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Jul-25-24 08:00AM	Lexicon Pharmaceuticals to Host Second Quarter 2024 Financial Results Conference Call and Webcast on August 1, 2024 (GlobeNewswire) +7.37%
Jul-17-24 11:15AM	FDA Accepts Lexicon's (LXRX) NDA for Type I Diabetes Drug (Zacks)
Jul-16-24 08:00AM	Lexicon Pharmaceuticals Receives December 20, 2024 PDUFA Goal Date for Sotagliflozin Type 1 Diabetes NDA Resubmission (GlobeNewswire) +5.19%
Jul-15-24 08:00AM	New Published Data Highlights Potential Cost-Savings of INPEFA (sotagliflozin) for Heart Failure (GlobeNewswire) +7.07%
Jul-08-24 09:15AM	Lexicon Board of Directors Appoints Mike Exton, Ph.D. as New Chief Executive Officer and Director (GlobeNewswire)
Jun-21-24 08:00AM	Lexicon Pharmaceuticals Resubmits Sotagliflozin NDA for Type 1 Diabetes (GlobeNewswire) +5.71%
Jun-19-24 08:00AM	Data From Lexicon's RELIEF-DPN 1 Phase 2 Study of LX9211 Published Today in Diabetes Care, a Peer-Reviewed Journal of the American Diabetes Association (GlobeNewswire)
Jun-18-24 08:00AM	Analysis of INPEFA (Sotagliflozin) Cost-Effectiveness Published in JACC: Heart Failure, the Peer-Reviewed Journal of the American College of Cardiology (GlobeNewswire)
Jun-14-24 08:00AM	Findings on the Burdens of Diabetic Peripheral Neuropathic Pain (DPNP) Among Three Lexicon-Sponsored Presentations at the 84th Scientific Sessions of the American Diabetes Association (GlobeNewswire)
May-30-24 04:45AM	Lexicon selects Medidata to advance Phase IIb non-opioid pain drug trial (Clinical Trials Arena)
May-29-24 07:30AM	Lexicon Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference 2024 (GlobeNewswire)
May-14-24 08:03AM	Lexicon Pharmaceuticals Says Post Hoc Analysis of Infepa Trial Showed Decreased Heart Failure Risk; Shares Gain Pre-Bell (MT Newswires)
07:00AM	New Post-Hoc Analysis of Pooled Phase 3 Data Shows That INPEFA (Sotagliflozin) Reduced Risk of Heart Failure Events in Patients With Preserved Ejection Fraction (GlobeNewswire)
May-09-24 07:30AM	Lexicon Pharmaceuticals to Participate in the Bank of America Securities Healthcare Conference 2024 (GlobeNewswire) +6.78%
May-06-24 10:05AM	Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Q1 2024 Earnings Call Transcript (Insider Monkey) +5.17%
May-03-24 07:46AM	Q1 2024 Lexicon Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
04:07AM	Lexicon Pharmaceuticals Inc (LXRX) Q1 2024 Earnings Call Transcript Highlights: Navigating ... (GuruFocus.com)
May-02-24 08:59PM	LXRX Stock Earnings: Lexicon Pharmaceuticals Meets EPS, Misses Revenue for Q1 2024 (InvestorPlace)
06:05PM	Lexicon Pharmaceuticals (LXRX) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
06:03PM	Lexicon Pharmaceuticals Reports Q1 2024 Earnings: Aligns with EPS Projections Amidst Strategic ... (GuruFocus.com)
05:00PM	Lexicon: Q1 Earnings Snapshot (Associated Press Finance)
04:05PM	Lexicon Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Apr-29-24 10:42AM	Lexicon Pharmaceuticals' Chief Executive Lonnel Coats to Retire (MT Newswires)
09:00AM	Lonnel Coats Retires as Chief Executive Officer and Board Member of Lexicon Pharmaceuticals (GlobeNewswire)
07:00AM	Lexicon Pharmaceuticals to Host First Quarter 2024 Financial Results Conference Call and Webcast on May 2, 2024 (GlobeNewswire)
Apr-18-24 08:00AM	Lexicon Pharmaceuticals to Host 2024 Investor Day (GlobeNewswire)
Apr-16-24 12:00PM	All You Need to Know About Lexicon (LXRX) Rating Upgrade to Buy (Zacks) -9.36%
Apr-03-24 08:00AM	Lexicon Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare Conference (GlobeNewswire) -7.69%
Mar-25-24 09:20AM	Clinical Data on the Impact of Sotagliflozin on Stroke and Heart Attack Risk Among Four Lexicon-Sponsored Presentations at the American College of Cardiology 73rd Annual Scientific Session & Expo (GlobeNewswire) -6.19%
Mar-13-24 12:45PM	Lexicon (LXRX) Dips on Post Hoc Analysis Data on Sotagliflozin (Zacks)
Mar-12-24 08:00AM	New Post Hoc Analysis of inTandem3 Study Demonstrates Improvements In Glycemic Control With Sotagliflozin Treatment in Patients With Type 1 Diabetes and Chronic Kidney Disease (GlobeNewswire) -10.32%
Mar-11-24 08:25AM	Lexicon Pharmaceuticals (LXRX) Reports Q4 Loss, Tops Revenue Estimates (Zacks) +29.49%
07:34AM	Lexicon: Q4 Earnings Snapshot (Associated Press Finance)
07:15AM	Lexicon Pharmaceuticals Reports Fourth Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
07:05AM	Lexicon Announces Oversubscribed $250 Million Private Placement of Equity Securities (GlobeNewswire)
07:00AM	Lexicon Preparing to Resubmit Sotagliflozin NDA for Type 1 Diabetes Following Feedback From FDA (GlobeNewswire)
Feb-29-24 10:00AM	Analysts Estimate Lexicon Pharmaceuticals (LXRX) to Report a Decline in Earnings: What to Look Out for (Zacks)
Feb-22-24 12:58PM	15 Hot Penny Stocks On the Move (Insider Monkey) -5.58%
Jan-31-24 05:06AM	3 Under-the-Radar Stocks With 340% to 762% Upside in 2024, According to Select Wall Street Analysts (Motley Fool) +6.25%
Jan-23-24 05:21AM	3 of the Fastest-Growing Stocks on the Planet in 2024 (Motley Fool) +15.94%
Jan-08-24 07:00AM	Lexicon Pharmaceuticals Provides Business and Pipeline Update at 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-26-23 05:06AM	3 Growth Stocks Expected to Skyrocket in 2024, According to Wall Street (Motley Fool) +7.63%
Dec-21-23 04:15PM	Lexicon Pharmaceuticals To Participate In The 42nd Annual JPMorgan Healthcare Conference (GlobeNewswire)
Nov-30-23 07:30AM	Lexicon Enrolls First Patient in Phase 2b Progress Study of LX9211 in Diabetic Peripheral Neuropathic Pain (DPNP) (GlobeNewswire)
Nov-22-23 07:30AM	Lexicon Pharmaceuticals to Participate in the 35th Annual Piper Sandler Healthcare Conference and the 6th Annual Evercore ISI HealthCONx Conference (GlobeNewswire)
Nov-15-23 01:03AM	Director Philippe Amouyal's Strategic 200,000 Share Purchase in Lexicon Pharmaceuticals Inc (GuruFocus.com)
Nov-12-23 02:10PM	INPEFA (sotagliflozin) Use Associated With Early Clinical Benefit in Heart Failure and Atherosclerotic Events in Analysis of Clinical Data (GlobeNewswire)
Nov-10-23 04:01PM	Lexicon Pharmaceuticals to Participate in the Jefferies London Healthcare Conference (GlobeNewswire) +5.94%
10:53AM	Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-08-23 09:45PM	Q3 2023 Lexicon Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents) -8.80% -9.21%
07:19AM	Lexicon: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	Lexicon Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
Nov-03-23 09:00AM	Lexicon Pharmaceuticals to Host Third Quarter 2023 Financial Results Conference Call and Webcast on November 8, 2023 (GlobeNewswire) +5.71%
Nov-02-23 09:00AM	Data on Early Clinical Benefit for INPEFA (Sotagliflozin) Will Be Among Five Lexicon-Sponsored Presentations at the American Heart Association Scientific Sessions 2023 (GlobeNewswire)
Nov-01-23 09:00AM	INPEFA (Sotagliflozin) Receives Coverage From Express Scripts on Its Basic and High Performance Formularies for Commercially Insured Patients (GlobeNewswire) +8.06%
Oct-31-23 04:01PM	Lexicon Strengthens Management Team With Two New Executives (GlobeNewswire)

Lexicon Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. Its drug candidates include: LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain, and Sotagliflozin, a treatment for heart failure and type 1 diabetes. The company was founded by Brian P. Zambrowicz and Arthur T. Sands on July 7, 1995 and is headquartered in The Woodlands, TX.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
COATS LONNEL	Former Affiliate	Aug 15 '24	Proposed Sale	1.60	300,000	480,000		Aug 15 04:47 PM
Swain Judith L	Director	Apr 28 '24	Option Exercise	0.00	8,032	0	48,364	Apr 29 04:21 PM
SOBECKI CHRISTOPHER J	Director	Apr 28 '24	Option Exercise	0.00	8,032	0	167,055	Apr 29 04:20 PM
LEFKOWITZ ROBERT J MD	Director	Apr 28 '24	Option Exercise	0.00	8,032	0	48,364	Apr 29 04:18 PM
DEBBANE RAYMOND	Director	Apr 28 '24	Option Exercise	0.00	8,032	0	1,348,879	Apr 29 04:17 PM
BARKER SAM L	Director	Apr 28 '24	Option Exercise	0.00	8,032	0	87,649	Apr 29 04:17 PM
Amouyal Philippe	Director	Apr 28 '24	Option Exercise	0.00	8,032	0	248,364	Apr 29 04:16 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

LXRX

Lexicon Pharmaceuticals Inc

Upgrade your FINVIZ experience